For example, in the PACIFIC trial, consolidative durvalumab after chemoradiotherapy significantly prolonged survival in NSCLC patients, demonstrating that PD-L1 blockade mitigates radiotherapy-associated T cell exhaustion. Here, CD274 is linked to non-small cell lung carcinoma.